JP2021527409A5 - - Google Patents

Info

Publication number
JP2021527409A5
JP2021527409A5 JP2020569179A JP2020569179A JP2021527409A5 JP 2021527409 A5 JP2021527409 A5 JP 2021527409A5 JP 2020569179 A JP2020569179 A JP 2020569179A JP 2020569179 A JP2020569179 A JP 2020569179A JP 2021527409 A5 JP2021527409 A5 JP 2021527409A5
Authority
JP
Japan
Prior art keywords
item
seq
cd79a
car according
isolated
Prior art date
Application number
JP2020569179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527409A (ja
JPWO2019241685A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037270 external-priority patent/WO2019241685A1/en
Publication of JP2021527409A publication Critical patent/JP2021527409A/ja
Publication of JP2021527409A5 publication Critical patent/JP2021527409A5/ja
Publication of JPWO2019241685A5 publication Critical patent/JPWO2019241685A5/ja
Priority to JP2025005370A priority Critical patent/JP7777245B2/ja
Withdrawn legal-status Critical Current

Links

JP2020569179A 2018-06-14 2019-06-14 Cd79aキメラ抗原受容体 Withdrawn JP2021527409A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005370A JP7777245B2 (ja) 2018-06-14 2025-01-15 Cd79aキメラ抗原受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685078P 2018-06-14 2018-06-14
US62/685,078 2018-06-14
PCT/US2019/037270 WO2019241685A1 (en) 2018-06-14 2019-06-14 Cd79a chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005370A Division JP7777245B2 (ja) 2018-06-14 2025-01-15 Cd79aキメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2021527409A JP2021527409A (ja) 2021-10-14
JP2021527409A5 true JP2021527409A5 (https=) 2022-06-21
JPWO2019241685A5 JPWO2019241685A5 (https=) 2022-06-21

Family

ID=68843258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569179A Withdrawn JP2021527409A (ja) 2018-06-14 2019-06-14 Cd79aキメラ抗原受容体
JP2025005370A Active JP7777245B2 (ja) 2018-06-14 2025-01-15 Cd79aキメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005370A Active JP7777245B2 (ja) 2018-06-14 2025-01-15 Cd79aキメラ抗原受容体

Country Status (13)

Country Link
US (2) US12060419B2 (https=)
EP (2) EP3806903B1 (https=)
JP (2) JP2021527409A (https=)
KR (1) KR102887853B1 (https=)
CN (1) CN112368021B (https=)
AU (1) AU2019287720C1 (https=)
BR (1) BR112020025439A2 (https=)
CA (1) CA3110836A1 (https=)
DK (1) DK3806903T5 (https=)
ES (1) ES2977415T3 (https=)
IL (2) IL312102B2 (https=)
SG (1) SG11202012155RA (https=)
WO (1) WO2019241685A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527409A (ja) 2018-06-14 2021-10-14 ブルーバード バイオ, インコーポレイテッド Cd79aキメラ抗原受容体
US20220280567A1 (en) * 2019-06-14 2022-09-08 2Seventy Bio, Inc. Compositions and methods for treating cancer
CN113527514B (zh) * 2021-06-30 2022-07-15 徐州医科大学 Gstp1在制备增效型CAR-T中的应用
CN113402618B (zh) * 2021-06-30 2022-06-10 徐州医科大学 Ski在制备增效型CAR-T细胞中的应用
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
CN116333117B (zh) * 2021-12-16 2024-04-26 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
KR102653905B1 (ko) 2023-08-24 2024-04-02 주식회사 티앤씨플랫폼 인공지능 모델 기반 it 인프라 장비의 상태 모니터링 및 유지 보수 정보 알람 서비스 제공 방법, 장치 및 시스템
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026050217A2 (en) * 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20110294217A1 (en) 2009-02-12 2011-12-01 Fred Hutchinson Cancer Research Center Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
US20140148361A1 (en) 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof
EP2633040B1 (en) 2010-10-27 2019-07-10 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
WO2012118717A2 (en) 2011-02-28 2012-09-07 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption
EP2694089B1 (en) 2011-04-05 2024-06-05 Cellectis New tale-protein scaffolds and uses thereof
EP2718432A4 (en) 2011-06-10 2015-01-07 Basf Plant Science Co Gmbh NUCLEASE FUSION PROTEIN AND USES THEREOF
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
JP6205363B2 (ja) * 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
RU2650811C2 (ru) 2012-02-24 2018-04-17 Фред Хатчинсон Кэнсер Рисерч Сентер Композиции и способы лечения гемоглобинопатии
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
JP6488283B2 (ja) 2013-05-31 2019-03-20 セレクティスCellectis C−cケモカイン受容体5型(ccr5)遺伝子を開裂するlaglidadgホーミングエンドヌクレアーゼおよびその用途
US10000746B2 (en) 2013-05-31 2018-06-19 Cellectis LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CA2945335A1 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
LT3134432T (lt) * 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
CA2968141C (en) * 2015-01-16 2020-08-04 Hsing-Mao CHU Molecular constructs with targeting and effector elements
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP4043556B1 (en) 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
GB201601075D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3331913A1 (en) * 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
KR102499191B1 (ko) 2016-03-18 2023-02-13 프레드 허친슨 캔서 센터 Cd20 면역요법을 위한 조성물 및 방법
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
CN105949317B (zh) 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
EP3336107A1 (en) 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
IL313037A (en) 2017-05-25 2024-07-01 2Seventy Bio Inc Cblb endonuclease variants, compositions, and methods of use
MA51428A (fr) 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
JP2021527409A (ja) 2018-06-14 2021-10-14 ブルーバード バイオ, インコーポレイテッド Cd79aキメラ抗原受容体
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
US20220280567A1 (en) * 2019-06-14 2022-09-08 2Seventy Bio, Inc. Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2021527409A5 (https=)
JP2018526028A5 (https=)
JP2017538710A5 (https=)
US11932873B2 (en) Reducing immune tolerance induced by PD-L1
JP2017522882A5 (https=)
RU2017106025A (ru) Химерные антигенные рецепторы к bcma
CN115386010B (zh) 靶向gprc5d的嵌合抗原受体及其用途
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP2019518425A5 (https=)
JP2021505137A5 (https=)
JP2025081512A5 (https=)
JPWO2020228825A5 (https=)
JPWO2019241685A5 (https=)
JPWO2020252110A5 (https=)
US20210246194A1 (en) Optimized gp41-Binding Molecules and Uses Thereof
US20180251530A1 (en) Anti-hiv dual specificity antibodies and methods of hiv treatment
RU2019107136A (ru) Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
JPWO2022046730A5 (https=)
JPWO2022195535A5 (https=)
JPWO2020172440A5 (https=)
US20240252643A1 (en) Gucy2c t cell-antigen couplers and uses thereof
EP4680753A2 (en) Dual targeted gene therapy
NZ728555B2 (en) Bcma chimeric antigen receptors
HK1228783A1 (en) Reducing immune tolerance induced by pd l1
HK1228783B (en) Reducing immune tolerance induced by pd l1